Your browser doesn't support javascript.
loading
Early temporal dynamics of cellular responses to SARS-CoV-2
Arinjay Banerjee; Nader El-Sayes; Patrick Budylowski; Daniel Richard; Hassaan Maan; Jennifer Aguiar; Kaushal Baid; Jann Catherine Ang; Benjamin J.-M. Tremblay; Sam Afkhami; Mehran Karimzadeh; Aaron T. Irving; Lily Yip; Mario A Ostrowski; Jeremy A Hirota; Robert Kozak; Terence D Capellini; Matthew S. Miller; Bo Wang; Samira Mubareka; Allison J. McGeer; Andrew G McArthur; Andrew C Doxey; Karen Mossman.
Afiliação
  • Arinjay Banerjee; McMaster University
  • Nader El-Sayes; McMaster University
  • Patrick Budylowski; University of Toronto
  • Daniel Richard; Harvard University
  • Hassaan Maan; Vector Institute
  • Jennifer Aguiar; University of Waterloo
  • Kaushal Baid; McMaster University
  • Jann Catherine Ang; McMaster University
  • Benjamin J.-M. Tremblay; University of Waterloo
  • Sam Afkhami; McMaster University
  • Mehran Karimzadeh; Vector Institute
  • Aaron T. Irving; Zhejiang University-University of Edinburgh Institute
  • Lily Yip; Sunnybrook Research Institute
  • Mario A Ostrowski; University of Toronto
  • Jeremy A Hirota; McMaster University
  • Robert Kozak; University of Toronto and Sunnybrook Research Institute
  • Terence D Capellini; Harvard University
  • Matthew S. Miller; McMaster University
  • Bo Wang; Vector Institute
  • Samira Mubareka; University of Toronto and Sunnybrook Research Institute
  • Allison J. McGeer; University of Toronto
  • Andrew G McArthur; McMaster University
  • Andrew C Doxey; University of Waterloo
  • Karen Mossman; McMaster University
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-158154
ABSTRACT
Type I interferons (IFNs) are our first line of defence against a virus. Protein over-expression studies have suggested the ability of SARS-CoV-2 proteins to block IFN responses. Emerging data also suggest that timing and extent of IFN production is associated with manifestation of COVID-19 severity. In spite of progress in understanding how SARS-CoV-2 activates antiviral responses, mechanistic studies into wildtype SARS-CoV-2-mediated induction and inhibition of human type I IFN responses are lacking. Here we demonstrate that SARS-CoV-2 infection induces a mild type I IFN response in vitro and in moderate cases of COVID-19. In vitro stimulation of type I IFN expression and signaling in human airway epithelial cells is associated with activation of canonical transcriptions factors, and SARS-CoV-2 is unable to inhibit exogenous induction of these responses. Our data demonstrate that SARS-CoV-2 is not adept in blocking type I IFN responses and provide support for ongoing IFN clinical trials. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC="FIGDIR/small/158154v2_ufig1.gif" ALT="Figure 1"> View larger version (35K) org.highwire.dtl.DTLVardef@193c540org.highwire.dtl.DTLVardef@7b106forg.highwire.dtl.DTLVardef@1741cfforg.highwire.dtl.DTLVardef@1bde68_HPS_FORMAT_FIGEXP M_FIG GRAPHICAL SUMMARY C_FIG
Licença
cc_no
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Estudo prognóstico Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Estudo prognóstico Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
...